THIS LETTER (INCLUDING ITS APPENDICES) IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. PLEASE READ IT CAREFULLY.

This letter should be read in conjunction with the Scheme Document circulated to Tate & Lyle Shareholders dated 3 July 2026, containing details of the Scheme, amongst other things.

If you are in any doubt as to the contents of this letter or the decision or action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser who, if you are taking advice in the United Kingdom, is authorised under the Financial Services and Markets Act 2000 (as amended from time to time) or, if you are taking advice outside the United Kingdom, from another appropriately authorised independent financial adviser.

3 July 2026

Dear Participant

The Tate & Lyle Sharesave Plan 2020 and the recommended acquisition of Tate & Lyle PLC by Ingredion Incorporated

On 8 June 2026, the boards of Tate & Lyle PLC ("**Tate & Lyle**") and Ingredion Incorporated ("**Ingredion**") announced that they had agreed the terms of a recommended acquisition by Ingredion to acquire the entire issued, and to be issued, ordinary share capital of Tate & Lyle (the "**Acquisition**"). If the Acquisition completes, it will result in Tate & Lyle and its subsidiaries becoming wholly-owned subsidiaries of Ingredion.

An explanation of the defined terms used in this letter is provided in Appendix D. Terms defined in the Scheme Document have the same meaning in this letter unless otherwise defined.

1 Why are we writing to you?

We are writing to explain how the Acquisition will affect your options granted under the Tate & Lyle Sharesave Plan 2020 which have an Option Price that is less than 595 pence (the "**Sharesave Options**") and the decisions you need to make in relation to them.

This letter applies to you if you hold either or both of:

(i) Sharesave Options which have already matured (meaning those Sharesave Options which are exercisable and for which the savings period has ended) ("**Matured Sharesave Options**"); or

(ii) Sharesave Options which have not matured yet (meaning those Sharesave Options which are not yet exercisable and for which the savings period is ongoing) ("**Unmatured Sharesave Options**").

- If you hold Matured Sharesave Options, please read Appendix A to this letter.
- If you hold Unmatured Sharesave Options, please read Appendix B to this letter.
- If you hold both Matured Sharesave Options and Unmatured Sharesave Options, then you must read both Appendix A and Appendix B.

For the avoidance of doubt, this letter only applies to any Matured Sharesave Options and/or Unmatured Sharesave Options that have an Option Price of less than 595 pence. If you hold any other options granted under the Sharesave with an Option Price of equal to or more than 595 pence, you will be contacted separately by Tate & Lyle on the effect of the Acquisition on those options. Please read that communication carefully.

If you participate in other Tate & Lyle share plans (i.e. the Tate & Lyle Performance Share Plan 2020 or its predecessor, the Tate & Lyle Performance Share Plan 2013), you will receive one or more further separate letters for these plans setting out the effect of the Acquisition on options and/or awards held under those plans. Please read each letter carefully.

Please read everything in this letter and the appendices carefully; the contents are very important.

PLEASE NOTE:

YOU WILL NEED TO TAKE ACTION TO RECEIVE PROFIT FROM YOUR MATURED SHARESAVE OPTIONS AND/OR YOUR UNMATURED SHARESAVE OPTIONS. THIS WILL NOT HAPPEN AUTOMATICALLY.

IF YOU TAKE NO ACTION, YOUR MATURED SHARESAVE OPTIONS WILL LAPSE ON THEIR NORMAL LAPSE DATES UNDER THE SHARESAVE RULES (UNLESS THEY LAPSE EARLIER UNDER THE SHARESAVE RULES), YOUR SAVINGS ACCOUNT WILL BE CLOSED AND YOU WILL NEED TO LOG IN TO YOUR COMPUTERSHARE ACCOUNT AT WWW.EQUATEPLUS.COM AND REQUEST THAT YOUR SAVINGS ARE RETURNED TO YOU BY CLICKING "SHARESAVE CLOSE OF ACCOUNT" ON YOUR SHARESAVE PLAN TILE.

IF YOU TAKE NO ACTION, YOUR UNMATURED SHARESAVE OPTIONS WILL LAPSE SIX MONTHS AFTER THE COURT SANCTION HEARING (UNLESS THEY LAPSE EARLIER UNDER THE SHARESAVE RULES INCLUDING IF THEIR NORMAL LAPSE DATE UNDER THE SHARESAVE RULES OCCURS BEFORE THE COURT SANCTION HEARING), YOUR SAVINGS ACCOUNT WILL BE CLOSED AND YOU WILL NEED TO LOG IN TO YOUR COMPUTERSHARE ACCOUNT AT WWW.EQUATEPLUS.COM AND REQUEST THAT YOUR SAVINGS ARE RETURNED TO YOU BY CLICKING "SHARESAVE CLOSE OF ACCOUNT" ON YOUR SHARESAVE PLAN TILE.

2 How does the Acquisition work?

It is intended that the Acquisition will take place through what is called a "scheme of arrangement" (the "**Scheme**"). This is a UK legal procedure under which Tate & Lyle Shares are automatically transferred to Ingredion in exchange for the consideration as set out in section 3 below. Amongst other things, the Acquisition has to be approved by Tate & Lyle Shareholders and by an order of an English court. The order is made by the Court during the Court Sanction Hearing.

The Acquisition is currently due to complete within a couple of days after the Court Sanction Hearing (the date on which the Acquisition completes is known as the "**Effective Date**"). If the Acquisition completes, it will result in Tate & Lyle and its subsidiaries becoming wholly-owned subsidiaries of Ingredion.

This letter and its appendices should be read together with the Scheme Document, a copy of which is also available on Tate & Lyle's website at https://www.tateandlyle.com/importantdisclaimer and Ingredion's website at https://www.ingredion.com/na/en-us/legal/offer-communications respectively. A copy of this letter is also available on the same websites.

3 What are the terms of the Acquisition?

The terms of, and conditions to, the Acquisition are set out in full in the Scheme Document. However, in summary, if the Acquisition goes ahead, each Tate & Lyle Shareholder will receive 595 pence in cash (the "**Cash Consideration**") for each Tate & Lyle Share they own.

4 When is the Acquisition likely to complete and become effective?

The Acquisition is subject to various Conditions (including antitrust and foreign direct investment approvals) as set out in further detail in the Scheme Document. The Acquisition is currently expected to complete (subject to the satisfaction or waiver (where applicable) of the Conditions) during the second half of 2027.

5 What if I have any questions?

Answers to Frequently Asked Questions are included in Appendix C. If you have any questions about your Matured Sharesave Options and/or your Unmatured Sharesave Options, what your choices are or how to exercise your Matured Sharesave Options and/or Unmatured Sharesave Options, please contact the EquatePlus Helpdesk on +44 (0)117 471 5346 or via the EquatePlus Helpchat on your EquatePlus account.

Please note that Tate & Lyle, Ingredion and/or Computershare cannot give you any legal, tax, investment or financial advice on the merits of the Acquisition, its effect on your Matured Sharesave Options and/or your Unmatured Sharesave Options or your choices.

If you are in doubt about what you should do, you should consult your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

6 Important notes

Nothing in this letter constitutes financial advice to any holder of shares, share awards or share options in Tate & Lyle.

If you require a hard copy of this letter, you can request one, free of charge, by contacting Computershare by calling +44 (0)117 471 5346, stating your name and the address to which the hard copy should be sent. You can also ask that any other documents, announcements and information to be sent to you in relation to the Acquisition should be sent to you in hard copy form.

If there are any differences between the information in this letter, the Sharesave Rules, or any relevant legislation, then the Sharesave Rules and the legislation (as applicable) will prevail.

Yours sincerely

Victoria Barlow

On behalf of Tate & Lyle PLC

Yours sincerely

Nancy Wolfe

On behalf of Ingredion Incorporated

Appendix A – Matured Sharesave Options

1 How does the Acquisition affect my Matured Sharesave Options?

Your Matured Sharesave Options are currently exercisable. Your Matured Sharesave Options are exercisable for six months after the date they became exercisable (unless they lapse earlier under the Sharesave Rules).

If the Court Sanction Hearing takes place and the Court sanctions the Scheme, this will not impact the period during which you can exercise your Matured Sharesave Options (i.e. the period will not be extended or reduced due to the Acquisition).

Any Matured Sharesave Options which are not exercised by the end of the six-month period after the date they became exercisable (unless they lapse earlier under the Sharesave Rules) will lapse and you will need to log in to your Computershare account at www.equateplus.com and request that your savings are returned to you by clicking "Sharesave close of account" on your Sharesave plan tile.

The terms of the Acquisition also permit Tate & Lyle Shareholders to receive:

- a final dividend in relation to the financial year ended 31 March 2026 of no greater than 13.2 pence per ordinary Tate & Lyle Share (the "**2026 Final Dividend**"); plus
- an interim dividend in relation to the six-month period ended 30 September 2026 of no greater than 6.8 pence per ordinary Tate & Lyle Share (the "**2027 Interim Dividend**" and together with the 2026 Final Dividend, the "**Permitted Dividends**"),

in each case provided the relevant Tate & Lyle Shareholder holds shares at the relevant dividend record time. The Permitted Dividends will be paid (subject to the approval of the Tate & Lyle Directors and, in the case of the 2026 Final Dividend, the requisite approval of Tate & Lyle Shareholders) in line with Tate & Lyle's ordinary course 2026 and 2027 financial year dividend calendars, in each case without any reduction in the Cash Consideration payable under the Acquisition.

You should note that if you hold Matured Sharesave Options, rather than Tate & Lyle Shares, at the relevant dividend record time you will not receive the relevant Permitted Dividend or any other value in respect of the relevant Permitted Dividend.

2 What are my choices?

- **<u>Choice A: Exercise your Matured Sharesave Options in the ordinary course</u>**

  You can exercise your Matured Sharesave Options now to buy Tate & Lyle Shares at the Option Price using your savings. You can do this for up to six months after the date your Matured Sharesave Options become exercisable (unless they lapse earlier under the Sharesave Rules).

  If you exercise your Matured Sharesave Options and sell the Tate & Lyle Shares acquired on exercise prior to the occurrence of the Court Sanction Hearing, the Tate & Lyle Shares will be sold at the market value on the date of sale and the cash proceeds will be paid to you as soon as practicable thereafter (less any applicable fees). You may not receive the same value as you would have done had you received the Cash Consideration.

  If you do not sell some or all of the Tate & Lyle Shares which you acquire on exercise, any Tate & Lyle Shares which you hold:

- at the Scheme Record Time will (assuming the Acquisition completes) be automatically purchased by Ingredion as part of the Acquisition and you will receive the Cash Consideration (595 pence) for each Tate & Lyle Share; and/or
- at the relevant dividend record date(s) will receive some or all of the Permitted Dividends.

If you want to exercise your Matured Sharesave Options, please access the EquatePlus Portal and complete the online exercise instruction before your Matured Sharesave Options lapse.

- **Choice B: Request the return of your savings contribution at any time (which will cause your Matured Sharesave Options to lapse)**

  If you would not like to exercise your Matured Sharesave Options and instead would like to cancel your savings contract and have your savings returned to you, you will need to log in to your Computershare account at www.equateplus.com and request that your savings are returned to you by clicking "Sharesave close of account" on your Sharesave plan tile. If you do so, your options will lapse on the date of such instruction.

  If you select Choice B, then unlike Choice A, you will not receive any Tate & Lyle Shares in respect of the Matured Sharesave Options, and therefore you will not profit from your Matured Sharesave Options (whether this be for the prevailing market value at the time of sale (assuming that market value is higher than the Option Price) or for the Cash Consideration of 595 pence per Tate & Lyle Share pursuant to the Acquisition).

3 What if I do nothing?

If you do nothing, the Matured Sharesave Options will lapse on their normal lapse dates (unless they lapse earlier under the Sharesave Rules). Your savings account will be closed and you will need to log in to your Computershare account at www.equateplus.com and request that your savings are returned to you by clicking "Sharesave close of account" on your Sharesave plan tile.

4 What if I leave the Tate & Lyle Group?

If you leave employment with the Tate & Lyle Group before the Court Sanction Hearing takes place and before you exercise your Sharesave Options, different rules may apply and you are advised to check the Sharesave Rules. For further information, please also refer to the Frequently Asked Questions section at Appendix C.

5 Proposal: recommendation

The Tate & Lyle Directors recommend that you select **Choice A** and exercise your Matured Sharesave Options before they lapse and, if you wish to receive some or all of any Permitted Dividends, that you exercise your Matured Sharesave Options in sufficient time to become a Tate & Lyle Shareholder prior to the relevant dividends' record date(s). You should, however, consider your own personal circumstances, including your tax position, when deciding if and when to exercise your Matured Sharesave Options.

The Tate & Lyle Directors, who have been so advised by Goldman Sachs and Greenhill as to the financial terms of the proposals, consider the terms of the proposals described above to be fair and reasonable in the context of the Acquisition. In providing their advice to the Tate & Lyle Directors, Goldman Sachs and Greenhill have taken into account the commercial assessments of the Tate & Lyle Directors. Both Goldman Sachs and Greenhill are providing independent financial advice to the Tate & Lyle Directors for the purposes of Rule 15.2 of the Takeover Code.

Appendix B – Unmatured Sharesave Options

1 How does the Acquisition affect my Unmatured Sharesave Options?

Completion of the Acquisition will change the usual treatment of your Unmatured Sharesave Options.

Your Unmatured Sharesave Options are not currently exercisable. Normally, you would continue saving until the end of your 3-year or 5-year savings contract and then decide whether to use your savings to exercise your Sharesave Options and buy Tate & Lyle Shares at the Option Price, or to let your Sharesave Options lapse and request that your savings are returned to you.

However, if the Court Sanction Hearing takes place before the end of your 3-year or 5-year savings contract and the Court sanctions the Scheme, your Unmatured Sharesave Options (meaning outstanding Sharesave Options which are not already exercisable) will become exercisable early to the extent of your savings at the date of exercise. Your Unmatured Sharesave Options will be exercisable for a period of six months starting on the date of the Court Sanction Hearing (unless they lapse earlier in accordance with the Sharesave Rules, including if they lapse on the normal lapse date six months after they first become exercisable at the end of the savings contract).

Any Unmatured Sharesave Options which are not exercised by the end of the six-month period after the date they become exercisable (unless they lapse earlier under the Sharesave Rules) will lapse and you will need to log in to your Computershare account at www.equateplus.com and request that your savings are returned to you by clicking "Sharesave close of account" on your Sharesave plan tile.

2 What are my choices for any Unmatured Sharesave Options?

- **Choice A: Apply to exercise your Unmatured Sharesave Options conditional on the Court sanctioning the Scheme**

  You will be able to elect in advance to exercise your Unmatured Sharesave Options conditional on the occurrence of the Court sanctioning the Scheme on the Court Sanction Hearing date. If you choose Choice A, you can continue to save until the Court Sanction Hearing date but you will lose out on the opportunity of saving until up to six months after the Court Sanction Hearing date under Choice B.

  The savings you have made at the date of exercise will be used to buy Tate & Lyle Shares at the Option Price on the Court Sanction Hearing date (unless your Unmatured Sharesave Options lapse earlier in accordance with the Sharesave Rules). The Tate & Lyle Shares which you receive on the exercise of your Unmatured Sharesave Options will be automatically purchased by Ingredion under the Acquisition. You will receive the Cash Consideration, which is 595 pence, for each Tate & Lyle Share that you receive on exercise of your Unmatured Sharesave Options.

- **Choice B: Apply in advance to exercise your Unmatured Sharesave Options at the latest practicable date after the Court sanctions the Scheme**

  You will be able to elect in advance to exercise your Unmatured Sharesave Options at the latest practicable date after the Court sanctions the Scheme on the Court Sanction Hearing date. If you do this, you can continue making monthly savings up to six months after the Court Sanction Hearing date.

If you choose Choice B, the savings which you have made to the date of exercise will be used to buy Tate & Lyle shares at the Option Price at the latest practicable date after the Court Sanction Hearing date (unless your Unmatured Sharesave Options have already reached the maximum savings permitted under your savings contract and been exercised, or lapse earlier under the Sharesave Rules). The Tate & Lyle shares which you receive on exercise of your Unmatured Sharesave Options will be automatically purchased by Ingredion pursuant to an amendment that is expected to be made to the Tate & Lyle articles of association. You will receive the Cash Consideration, which is 595 pence, for each Tate & Lyle share that you receive on exercise of your Unmatured Sharesave Options. You will not be able to retain any Tate & Lyle shares.

Compared to Choice A, choosing Choice B may allow you to buy more Tate & Lyle shares (and therefore receive more Cash Consideration in aggregate) as you can make further monthly savings contributions. However, you will receive the Cash Consideration later.

- **Choice C: Apply to exercise your Unmatured Sharesave Options at a time of your choosing between the Court Sanction Hearing date and their lapse date (normally six months later)**

  You can also choose to exercise your Unmatured Sharesave Options at an earlier date during the six months after the Court Sanction Hearing date, or, if earlier, during the six months after your Unmatured Sharesave Options mature (unless your Unmatured Sharesave Options lapse earlier under the Sharesave Rules). You can do so by submitting an election via your EquatePlus Account. You will receive correspondence from Computershare following the Court Sanction Hearing date with instructions on how to do this.

  If you choose Choice C, the savings which you have made to the date of exercise will be used to buy Tate & Lyle shares at the Option Price. There will be monthly batches in which you can exercise your Sharesave Options. The cut-off dates for exercising your Unmatured Sharesave Options as part of the monthly batches will be communicated to you shortly following the Court Sanction Hearing date. If you choose Choice C, therefore, and your Unmatured Sharesave Options are exercised as part of the relevant monthly batch at such time, then the Tate & Lyle shares which you receive on exercise of your Unmatured Sharesave Options will be automatically purchased by Ingredion pursuant to an amendment that is expected to be made to the Tate & Lyle articles of association. You will receive the Cash Consideration, which is 595 pence, for each Tate & Lyle share that you receive on exercise of your Unmatured Sharesave Options. You will not be able to retain any Tate & Lyle shares.

  If you decide to exercise your Unmatured Sharesave Options under Choice C:

  (i) compared to Choice A, you may be able to buy more Tate & Lyle shares (and therefore receive more Cash Consideration in aggregate) as you can make further monthly savings contributions, but you will receive the Cash Consideration later; and

  (ii) compared to Choice B, you would buy fewer Tate & Lyle shares (and therefore receive less Cash Consideration in aggregate) as you would have made fewer monthly savings contributions, but you will receive the Cash Consideration earlier.

Further details on how you can choose Choice C and exercise your Unmatured Sharesave Options at any time between the Court Sanction Hearing date and their lapse date will be shared with you in due course.

- **Choice D: Request the return of your savings contributions at any time (which will cause your option to lapse)**

  If you would like to cancel your savings contract and have your savings returned to you, you will need to log in to your Computershare account at www.equateplus.com and request that your savings are returned to you by clicking "Sharesave close of account" on your Sharesave plan tile. If you do so, your options will lapse on the date of such instruction.

  If you select Choice D, then unlike Choice A, Choice B and Choice C, you will not receive any Tate & Lyle shares in respect of the Unmatured Sharesave Options, and therefore you will not profit from your Unmatured Sharesave Options and you will not be able to receive any Cash Consideration in connection with your Unmatured Sharesave Options.

3 What if I do nothing?

If you do not select any of the Choices above before the relevant deadlines and in accordance with the process that shall be set out to you, then your Sharesave Options will lapse six months after the Court Sanction Hearing date (or earlier under the Sharesave Rules). Your savings account will be closed and you will need to log in to your Computershare account at www.equateplus.com and request that your savings are returned to you by clicking "Sharesave close of account" on your Sharesave plan tile.

4 What if I leave the Tate & Lyle Group?

If you leave employment with the Tate & Lyle Group before the Court Sanction Hearing takes place and before you exercise your Sharesave Options, different rules may apply and you are advised to check the Sharesave Rules. For further information, please also refer to the Frequently Asked Questions section at Appendix C.

5 How do I make my Choice?

You do not need to do anything now.

However, you will be sent further information by Computershare in due course on the process by which you can select one of the Choices above, including when you can make that Choice as well as the relevant deadline by which you must make that Choice.

It is anticipated that you will be able to make that choice during a window of several months. However, at minimum you will have at least three weeks prior to the Court Sanction Hearing taking place to make your choice.

6 Proposal: recommendation

The Tate & Lyle Directors recommend that you exercise your Unmatured Sharesave Options before they lapse, **by selecting Choice A, Choice B or Choice C**. You should, however, consider your own personal circumstances, including your tax position, when deciding if and when to exercise your Unmatured Sharesave Options when or after they have become exercisable.

The Tate & Lyle Directors, who have been so advised by Goldman Sachs and Greenhill as to the financial terms of the proposals, consider the terms of the proposals described above to be fair and reasonable in the context of the Acquisition. In providing their advice to the Tate & Lyle Directors, Goldman Sachs and Greenhill have taken into account the commercial assessments of the Tate & Lyle Directors. Both Goldman Sachs and Greenhill are providing independent financial advice to the Tate & Lyle Directors for the purposes of Rule 15.2 of the Takeover Code.

Appendix C – Frequently Asked Questions

Note that this Appendix C - Frequently Asked Questions applies for both Matured Sharesave Options and/or Unmatured Sharesave Options.

- **When is the Effective Date likely to take place?**

  The Effective Date is currently expected to take place in the second half of 2027 subject to the satisfaction or waiver (where applicable) of the Conditions. The Expected Timetable of Principal Events is available in the front section of the Scheme Document.

- **What if the Acquisition is not sanctioned by the Court?**

  In this letter, it is generally assumed that the Court will sanction the Scheme at the Court Sanction Hearing. If the Court Sanction Hearing does not occur and/or the Court does not sanction the Scheme for any reason:

  (i) any Matured Sharesave Options that you have not yet exercised will continue (including as to their lapse) as normal under the Sharesave Rules; and

  (ii) any Unmatured Sharesave Options will continue (including as to their lapse) as normal under the Sharesave Rules and will not become exercisable early as a result of the Acquisition.

- **What happens if I leave employment with the Tate & Lyle Group?**

  The leaver provisions under the Sharesave Rules will apply to your Sharesave Options in the normal way.

  This means that:

  (i) If you leave for a "good leaver" reason under the Sharesave Rules (for example, injury, disability or redundancy within the meaning of the Employment Rights Act 1996), or, if you leave more than three years after the date your Sharesave Options were granted for any reason not involving misconduct, your Sharesave Options will be exercisable until the earliest of: (i) six months from the maturity date of the Sharesave Options; and (ii) six months from the date on which you leave employment with the Tate & Lyle Group, to the extent of the savings which you have accumulated on the date of exercise; and

  (ii) If you leave for any other reason, your unexercised Sharesave Options will lapse when you leave employment with the Tate & Lyle Group and you will need to log in to your Computershare account at www.equateplus.com and request that your savings are returned to you by clicking “Sharesave close of account” on your Sharesave plan tile.

  For Unmatured Sharesave Options, if you leave the Tate & Lyle Group before the Court Sanction Hearing date, your Unmatured Sharesave Options could lapse before that date. If that happens, any Choice A or Choice B instruction you might have made prior to such time will not take effect. In this case, if you wish to exercise your Sharesave Options, you will need to log into your Computershare account at www.equateplus.com and complete the “Sharesave leaver” task which will be presented to you.

  Special rules apply on death.

- **What if I am a PDMR or an insider?**

  If you are a Person Discharging Managerial Responsibilities ("**PDMR**") or if the Tate & Lyle Share Dealing Code applies to you, you must obtain permission to apply to exercise your Sharesave Options via the Tate & Lyle Project Portal at www.tateandlyleprojectportal.com. Further detail will be provided to you in due course. PDMRs will not be permitted to apply to exercise their Sharesave Options during a closed period.

- **If I currently hold Unmatured Sharesave Options, but these mature and become Matured Sharesave Options prior to the Court Sanction Hearing, what does this mean?**

  If, at the date of this letter you are holding Unmatured Sharesave Options, then Appendix B applies to those Unmatured Sharesave Options. If, however, these Unmatured Sharesave Options eventually mature in the ordinary course, then from such date, you should refer to Appendix A in respect of these now Matured Sharesave Options.

  If you make an election in respect of an Unmatured Sharesave Option that subsequently matures before the Court Sanction Hearing, you will be contacted at such time to discuss your election.

- **What is the impact of the Acquisition on bonus and interest payments?**

  Where an option has matured, you will still be entitled to the bonus payment and, in respect of early exercises / early returns of savings, you may be entitled to an interest payment (albeit on a lower basis) depending upon how long you have been saving for.

- **What if I have Sharesave options with an Option Price of equal to or more than 595 pence?**

  You will receive a separate letter about these options. Please read that letter carefully.

- **What if I participate in other Tate & Lyle share plans?**

  If you participate in the Tate & Lyle Performance Share Plan 2020 (or its predecessor, the Tate & Lyle Performance Share Plan 2013), you will receive one or more further separate letters about your other options and/or awards. Please read those letters carefully as the treatment of any options and/or awards under those plans will be different from the treatment of your Sharesave Options.

Appendix D – Glossary

“**Acquisition**” has the meaning given to it at the start of this letter;

“**Business Day**” means a day (other than Saturdays, Sundays and public holidays) on which banks are generally open for business in London;

“**Cash Consideration**” has the meaning given to it in section 3 of this letter;

“**Companies Act 2006**” means the UK Companies Act 2006, as amended;

“**Court**” means the High Court of Justice in England and Wales;

“**Court Sanction Hearing**” means the hearing by the Court to sanction the Scheme under Part 26 of the Companies Act 2006;

“**Goldman Sachs**” means Goldman Sachs International;

“**Greenhill**” means Greenhill & Co. International LLP;

“**Ingredion**” means Ingredion Incorporated, a corporation incorporated in Delaware, United States, with its principal executive offices located at 5 Westbrook Corporate Center, Westchester, Illinois 60154, United States, and listed on the New York Stock Exchange (NYSE: INGR);

“**Ingredion Directors**” means the directors of Ingredion, whose names are set out in the Scheme Document or, where the context so requires, the directors of Ingredion from time to time;

“**Ingredion Group**” means Ingredion and its subsidiaries, subsidiary undertakings, associated undertakings and any other body corporate, partnership, joint venture or person in which Ingredion and/or such subsidiaries or undertakings (aggregating their interests) have a Significant Interest;

“**Matured Sharesave Options**” has the meaning given to it in section 1 of this letter;

“**Option Price**” means the price per Tate & Lyle Share at which a participant can buy Tate & Lyle Shares pursuant to a Matured Sharesave Option or Unmatured Sharesave Option (as applicable);

“**Sharesave**” means the Tate & Lyle Sharesave Plan 2020;

“**Sharesave Rules**” means the rules of the Tate & Lyle Sharesave Plan 2020;

“**Scheme**” means the procedure by which Ingredion will become the holder of the entire issued and to be issued share capital of Tate & Lyle, as further described in section 2 of this letter;

“**Scheme Document**” means the document to be sent to Tate & Lyle Shareholders containing, amongst other things, the Scheme;

“**Scheme Record Time**” means the record time for the Scheme, currently expected to be 6.00 p.m. (London time) on the Business Day immediately after the date on which the Court makes its order sanctioning the Scheme;

“**Significant Interest**” means, in relation to an undertaking, a direct or indirect interest of 20 per cent. or more of the total voting rights conferred by the equity share capital (as defined in section 548 of the Companies Act 2006) of such undertaking;

“**Takeover Code**” means the City Code on Takeovers and Mergers of the United Kingdom issued by the Panel, as amended from time to time;

“**Tate & Lyle**” means Tate & Lyle PLC, a public company incorporated in England and Wales with registered number 00076535 and with its registered address at 5 Marble Arch, London W1H 7EJ, United Kingdom;

“**Tate & Lyle Directors**” means the directors of Tate & Lyle, whose names are set out in the Scheme Document or, where the context so requires, the directors of Tate & Lyle from time to time;

“**Tate & Lyle Group**” means Tate & Lyle and its subsidiaries, subsidiary undertakings, associated undertakings and any other body corporate, partnership, joint venture or person in which Tate & Lyle and/or such subsidiaries or undertakings (aggregating their interests) have a Significant Interest;

“**Tate & Lyle Shareholders**” means the registered holders of Tate & Lyle Shares from time to time;

“**Tate & Lyle Shares**” means the existing unconditionally allotted or issued fully paid ordinary shares of 29 1/6 pence each in the capital of Tate & Lyle and any further such ordinary shares which are unconditionally allotted or issued before the Scheme Record Time; and

“**Unmatured Sharesave Options**” has the meaning given to it in section 1 of this letter.

Notes

The release, publication or distribution of this letter (in whole or in part) in, into or from jurisdictions other than the United Kingdom may be restricted by the laws of those jurisdictions and therefore persons into whose possession this letter comes should inform themselves about, and observe, such restrictions. Any failure to comply with these restrictions may constitute a violation of the applicable laws of any such jurisdiction.

This letter is not intended to and does not constitute or form part of any offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities or the solicitation of an offer to buy any securities pursuant to this letter or otherwise.

The Tate & Lyle Directors, whose names are set out in the Scheme Document, accept responsibility for the information contained in this letter, including expressions of opinion, other than information for which responsibility is taken by the Ingredion Directors. To the best of the knowledge and belief of the Tate & Lyle Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this letter for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

The Ingredion Directors, whose names are set out in the Scheme Document, accept responsibility for the information contained in this letter (including any expressions of opinion) relating to Ingredion, the Ingredion Group, the Ingredion Directors and their respective close relatives (as defined in the Takeover Code), related trusts and other persons acting in concert with them. To the best of the knowledge and belief of the Ingredion Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this letter for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

Goldman Sachs, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Tate & Lyle and no one else in connection with the matters referred to in this letter and will not be responsible to anyone other than Tate & Lyle for providing the protections afforded to clients of Goldman Sachs, or for providing advice in connection with the matters referred to in this letter.

Greenhill, an affiliate of Mizuho Financial Group, Inc., and which is authorised and regulated in the UK by the Financial Conduct Authority, is acting exclusively for Tate & Lyle and for no one else in connection with the matters referred to in this letter and will not be responsible to anyone other than Tate & Lyle for providing the protections afforded to clients of Greenhill nor for providing advice in connection with the matters referred to in this letter.

Each of Goldman Sachs and Greenhill has given, and has not withdrawn its written consent to the inclusion herein of the references to its name in the form and context in which such references appear.

Accidental omission to despatch this letter to, or any failure to receive the same by, any person to whom the proposal set out in this letter is made or should be made, shall not invalidate the proposal in any way.

This document shall be governed by and construed in accordance with English law and any dispute arising in connection therewith, including non-contractual disputes, is subject to the exclusive jurisdiction of the courts of England and Wales.